Main menu
Edison Group
  • Home
  • Sparks
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Sareum Holdings

    MCap

    GBP23m

    Last close

    GBP0.16

    ▲ −0.75 (−4.41%)

    Metals One

    MCap

    —

    Last close

    GBP0.01

    ▲ 0.18 (19.44%)

    Electro Optic Systems

    MCap

    AUD1,639m

    Last close

    AUD8.72

    ▲ 0.23 (2.71%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Sparks commentary - Oryzon Genomics

Healthcare

Sparks - Oryzon Genomics

More on this equity
testalize-me-0jE8ynV4mis-unsplash
Oryzon (BME: ORY) strengthens iadademstat patent portfolio
Published by Arron Aatkar, PhD

Oryzon Genomics has announced the receipt of a ‘Decision to grant’ from the Japanese Patent Office for its patent application ‘Combinations of iadademstat for cancer therapy’. This covers the use of iadademstat in combination with immune checkpoint inhibitors such as atezolizumab and durvalumab in small cell lung cancer, an indication that Oryzon is pursuing in active clinical trials. Once granted, this patent will remain in place until at least 2040, excluding any other potential patent term extensions. Management noted that it has secured corresponding patents in Europe, Japan, Australia and Russia, with additional applications pending in other key regions.

Next Sparks Commentary in this sector >

Latest

Healthcare | Comment

BioVersys (SIX:BIOV) moves closer to Phase III with CTA filing

Healthcare | Comment

Basilea (SIX: BSLN) enters into antibiotic discovery partnership with Phare Bio

Consumer | Comment

BAT (LSE: BATS) – FY25 profit in line with guidance, FY26 guidance at low end of medium-term growth range

Healthcare | Comment

OSE Immunotherapeutics (PAR: OSE) – AbbVie partnership amendment

Industrials | Comment

Ocean Wilsons (LON: OCN) – Suspension, de-listing and cancellation of trading